NASDAQ:EPZM

Epizyme Stock Forecast, Price & News

$12.13

+0.28 (+2.36 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$11.87

Now: $12.13▼

$12.25

50-Day Range

$10.34

MA: $12.29▼

$13.77

52-Week Range

$9.90

Now: $12.13▼

$27.82

Volume300,702 shs

Average Volume1.03 million shs

Market Capitalization$1.23 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.88

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with platinum-resistant solid tumors, such as small-cell lung cancer, triple-negative breast cancer, and ovarian cancer. In addition, it develops Tazemetostat in patients with castration-resistant prostate cancer; and pediatrics with INI1-negative tumors. Further, the company develops pinometostat for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor for patients with solid tumors and blood cancers; and PRMT1 inhibitor for solid tumors and DLBCL. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; and Eisai Co. Ltd. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Epizyme has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.88, Epizyme has a forecasted upside of 121.6% from its current price of $12.13.
Amount of Analyst Coverage
Epizyme has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Epizyme has received 469 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Epizyme has received 369 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Epizyme has received 55.97% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote “Outperform” if you believe EPZM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Epizyme does not currently pay a dividend.
Dividend Growth
Epizyme does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Epizyme insiders have bought 386.69% more of their company's stock than they have sold. Specifically, they have bought $60,350.00 in company stock and sold $12,400.00 in company stock.
Percentage Held by Insiders
Only 16.30% of the stock of Epizyme is held by insiders.
Percentage Held by Institutions
90.93% of the stock of Epizyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Epizyme are expected to grow in the coming year, from ($2.37) to ($2.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Epizyme is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Epizyme is -5.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Epizyme has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EPZM

Previous Symbol

CUSIPN/A

CIK1571498

Webwww.epizyme.com

Phone617-229-5872

Employees203

Debt

Debt-to-Equity Ratio0.27

Current Ratio11.57

Quick Ratio11.25

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$23.80 million

Price / Sales51.77

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.22 per share

Price / Book3.77

Profitability

EPS (Most Recent Fiscal Year)($1.93)

Net Income$-170,290,000.00

Net Margins-1,459.72%

Return on Equity-72.65%

Return on Assets-49.31%

Miscellaneous

Outstanding Shares101,581,000

Market Cap$1.23 billion

Next Earnings Date2/22/2021 (Estimated)

OptionableOptionable

$12.13

+0.28 (+2.36 %)

(As of 11/27/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

How has Epizyme's stock been impacted by COVID-19 (Coronavirus)?

Epizyme's stock was trading at $18.46 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EPZM stock has decreased by 34.3% and is now trading at $12.13.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Epizyme?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Epizyme or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Epizyme?

Wall Street analysts have given Epizyme a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Epizyme wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Epizyme's next earnings date?

Epizyme is scheduled to release its next quarterly earnings announcement on Monday, February 22nd 2021.
View our earnings forecast for Epizyme.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) released its earnings results on Friday, November, 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.60) by $0.05. The biopharmaceutical company earned $3.60 million during the quarter, compared to the consensus estimate of $5.89 million. Epizyme had a negative return on equity of 72.65% and a negative net margin of 1,459.72%. The firm's revenue for the quarter was down 36.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.54) earnings per share.
View Epizyme's earnings history.

What price target have analysts set for EPZM?

8 equities research analysts have issued 1-year target prices for Epizyme's shares. Their forecasts range from $16.00 to $36.00. On average, they expect Epizyme's share price to reach $26.88 in the next twelve months. This suggests a possible upside of 121.6% from the stock's current price.
View analysts' price targets for Epizyme.

Who are some of Epizyme's key competitors?

Some companies that are related to Epizyme include Schrödinger (SDGR), Emergent BioSolutions (EBS), PTC Therapeutics (PTCT), Hutchison China MediTech (HCM), Insmed (INSM), GW Pharmaceuticals (GWPH), TG Therapeutics (TGTX), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Arena Pharmaceuticals (ARNA), Hypera (HYPMY), Legend Biotech (LEGN), MorphoSys (MOR), FibroGen (FGEN) and Apellis Pharmaceuticals (APLS).
View all competitors.

What other stocks do shareholders of Epizyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

Who are Epizyme's key executives?

Epizyme's management team includes the following people:

Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 52, Pay $1.01M)
Mr. Paolo Tombesi, Chief Financial Officer (Age 56, Pay $628.41k)
Mr. Matthew E. Ros, Chief Strategy & Bus. Officer (Age 53, Pay $644.06k)
Dr. Shefali Agarwal M.D., MPH, Chief Medical Officer (Age 46, Pay $737.27k)
Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory Board
Dr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory Board
Mr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 39)
Dr. Jeffery L. Kutok, Chief Scientific Officer (Age 53)
Jason Fredette, VP of Investor Relations
Mr. John F. Weidenbruch, Gen. Counsel (Age 59)

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), State Street Corp (4.38%), MPM Oncology Impact Management LP (2.81%), Victory Capital Management Inc. (2.73%), Morgan Stanley (1.43%) and Charles Schwab Investment Management Inc. (0.59%). Company insiders that own Epizyme stock include Carl Goldfischer, David M Mott, Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends for Epizyme.

Which institutional investors are selling Epizyme stock?

EPZM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., AQR Capital Management LLC, Wells Fargo & Company MN, ExodusPoint Capital Management LP, Alps Advisors Inc., Alps Advisors Inc., Dupont Capital Management Corp, and UBS Asset Management Americas Inc.. Company insiders that have sold Epizyme company stock in the last year include Joseph Beaulieu, Matthew Ros, Paolo Tombesi, Robert B Bazemore, and Shefali Agarwal.
View insider buying and selling activity for Epizyme.

Which institutional investors are buying Epizyme stock?

EPZM stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, State Street Corp, MPM Oncology Impact Management LP, Victory Capital Management Inc., CIBC Private Wealth Group LLC, Point72 Asset Management L.P., Williams Jones Wealth Management LLC., and Aigen Investment Management LP. Company insiders that have bought Epizyme stock in the last two years include Carl Goldfischer, and David M Mott.
View insider buying and selling activity for Epizyme.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $12.13.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.23 billion and generates $23.80 million in revenue each year. The biopharmaceutical company earns $-170,290,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Epizyme employs 203 workers across the globe.

What is Epizyme's official website?

The official website for Epizyme is www.epizyme.com.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings